Jamie Scott, an NHS worker diagnosed with metastatic ocular melanoma, is among patients compelled to self-fund a life-saving treatment approved for NHS use but not routinely accessible, highlighting urgent disparities in rare cancer care.
Jamie Scott, a 49-year-old NHS communications worker diagnosed with ocular melanoma in 2011, is facing challenges securing access to a potentially life-extending treatment for her cancer that has spread to her liver. Despite surgery to remove her eye, the metastatic nature of the disease means she now requires chemosaturation therapy, also known as percutaneous hepatic perfusion, a specialised high-dose chemotherapy administered directly to the liver. This treatment has been approved for NHS use under “special arrangements” by the National Institute for Health and Care Excellence (NICE) since April 2021 but is not routinely available on the NHS. Jamie has been told she cannot access it through NHS channels and must independently raise the £120,000 required for treatment, a financial hurdle she describes as overwhelming and desperate.
Chemosaturation therapy isolates the liver during treatment, allowing larger doses of chemotherapy to be delivered with fewer systemic side effects compared to conventional chemotherapy. International data and expert opinions indicate that this approach controls tumours in nearly nine out of ten patients with ocular melanoma metastasised to the liver, with some patients achieving survival over multiple years. Retired liver surgeon Dr Neil Pearce emphasises that the procedure is usually well-tolerated with short recovery times, meaning patients can quickly return to their lives and families. However, UK patients face a stark disparity as they are often excluded from NHS funding for the treatment, having to self-fund or seek treatment abroad, whereas international patients can travel to the UK to access it.
The charity Ocular Melanoma UK (OMUK), which supports patients with this rare and aggressive cancer, is campaigning for urgent NHS action to enable patient access to chemosaturation therapy. OMUK highlights that around 600 people are diagnosed with ocular melanoma annually in the UK, with up to half developing secondary liver disease, which is often incurable without effective liver-directed treatments. The charity points to NICE’s recommendation that the treatment should be made available under “special arrangements” while further evidence on its clinical and cost effectiveness is gathered. Nonetheless, concerns about treatment complications have contributed to hesitancy in commissioning the therapy routinely on the NHS.
Jo Gumbs, chief executive of OMUK, sharply criticises NHS England for failing to act, stating that patients with one of the least survivable cancers are being forced into fundraising to access the only treatment proven to extend life. She has called on the Secretary of State for Health and Social Care to intervene before more lives are lost needlessly. Meanwhile, Jamie Scott’s situation epitomises the tragic consequences of this systemic gap in care—she expressed deep hopelessness, acknowledging that without the treatment or enrolment in a clinical trial, she is “waiting to die.”
Existing treatment options for advanced ocular melanoma metastatic to the liver, as outlined by Macmillan Cancer Support and international cancer centres like Memorial Sloan Kettering and Massachusetts General Hospital, include liver-directed therapies such as liver resection, radiofrequency ablation, chemoembolisation, and chemosaturation. These therapies aim to prolong survival and improve quality of life, with chemosaturation offering a particularly targeted and intensive option for patients with liver metastases. The Massachusetts General Hospital programme, for instance, administers the FDA-approved liver-focused chemotherapy in multiple cycles to enhance therapeutic response while minimising systemic toxicity, underscoring the evolving landscape of care for this challenging disease.
Despite the medical promise of chemosaturation, the UK’s uneven access to this treatment reflects broader issues in rare cancer management and NHS funding structures. The fact that patients who have contributed to the NHS, like Jamie Scott, must now raise hundreds of thousands of pounds to afford standard-of-care therapies spotlights a critical healthcare inequity. Experts and advocates continue to campaign for changes to NHS policies to ensure equitable and timely treatment access for patients with rare cancers such as ocular melanoma, aiming to prevent further tragic delays and improve survival outcomes across the country.
📌 Reference Map:
- Paragraph 1 – [1] (The Independent), [2] (Telford Live)
- Paragraph 2 – [1] (The Independent), [3] (OMUK), [6] (Massachusetts General Hospital)
- Paragraph 3 – [1] (The Independent), [3] (OMUK), [4] (Standard)
- Paragraph 4 – [1] (The Independent), [3] (OMUK)
- Paragraph 5 – [5] (Macmillan Cancer Support), [6] (Massachusetts General Hospital), [7] (Memorial Sloan Kettering)
- Paragraph 6 – [1] (The Independent), [3] (OMUK), [4] (Standard)
Source: Noah Wire Services
Noah Fact Check Pro
The draft above was created using the information available at the time the story first
emerged. We’ve since applied our fact-checking process to the final narrative, based on the criteria listed
below. The results are intended to help you assess the credibility of the piece and highlight any areas that may
warrant further investigation.
Freshness check
Score:
8
Notes:
The narrative appears to be original, with no evidence of prior publication. The earliest known publication date is October 27, 2025. The report is based on a press release from Ocular Melanoma UK (OMUK), which typically warrants a high freshness score. However, the report includes updated data but recycles older material, which may justify a higher freshness score but should still be flagged. No discrepancies in figures, dates, or quotes were found. The narrative has not appeared more than 7 days earlier. No republishing across low-quality sites or clickbait networks was identified. The report includes updated data but recycles older material, which may justify a higher freshness score but should still be flagged.
Quotes check
Score:
9
Notes:
The direct quotes from Jamie Scott and Jo Gumbs appear to be original, with no identical matches found in earlier material. This suggests potentially original or exclusive content.
Source reliability
Score:
9
Notes:
The narrative originates from The Independent, a reputable organisation, which strengthens its reliability. The report is based on a press release from Ocular Melanoma UK (OMUK), a legitimate charity supporting patients with ocular melanoma, further enhancing the credibility of the information.
Plausability check
Score:
8
Notes:
The claims regarding Jamie Scott’s fundraising efforts and the challenges in accessing chemosaturation therapy are plausible and align with known issues in NHS funding for rare cancers. The report lacks supporting detail from other reputable outlets, which is a concern. The language and tone are consistent with the region and topic. The structure is focused and relevant, without excessive or off-topic detail. The tone is appropriately dramatic, reflecting the gravity of the situation.
Overall assessment
Verdict (FAIL, OPEN, PASS): PASS
Confidence (LOW, MEDIUM, HIGH): HIGH
Summary:
The narrative is original and based on a reputable source, with plausible claims and no significant issues identified. The lack of supporting detail from other reputable outlets is a minor concern but does not undermine the overall credibility.
Supercharge Your Content Strategy
Feel free to test this content on your social media sites to see whether it works for your community.
